Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
暂无分享,去创建一个
P. Albers | M. Stöckle | T. Kälble | C. Seif | M. Grimm | M. Spahn | M. Retz | A. Heidenreich | J. Gschwend | J. Lehmann | M. Gerber | C. Greb | S. Krege | C. Wülfing | J. Kamradt | G. Fechner | B. Volkmer | N. Nürnberg | H. Suttmann | M. Hack | A. Odenthal | C. F. Fieseler | H. Schulte-Baukloh | Jürgen E. Gschwend | C. Fieseler
[1] N. Shinohara,et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. , 2007, European urology.
[2] C. Dinney,et al. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. , 2006, The Journal of urology.
[3] J. McKiernan,et al. Novel therapeutics in the treatment of bladder cancer , 2004, Current opinion in urology.
[4] R. Millikan,et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. , 2004, The Journal of urology.
[5] R. Millikan,et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? , 2003, The Journal of urology.
[6] V. I. Dronov,et al. [Radical cystectomy in the treatment of invasive bladder cancer]. , 2003, Voenno-meditsinskii zhurnal.
[7] V. Reuter,et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. , 2003, The Journal of urology.
[8] Terry L. Smith,et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Gerhard Jakse,et al. Guidelines on bladder cancer. , 2002, European urology.
[10] L. Collette,et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Bajorin,et al. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.
[12] H. Rübben,et al. Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. , 2001, Urology.
[13] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Bacik,et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Dimopoulos,et al. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. , 1994, The Journal of urology.
[16] L. Einhorn,et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] F. Freiha,et al. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. , 1993, The Journal of urology.
[18] C. Logothetis,et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] N. Geller,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.
[20] D. Johnson,et al. Long-term results following thoracotomy for metastatic bladder cancer. , 1982, Urology.